Isotechnika receives $21.9M milestone from Roche

Guest Contributor
May 22, 2003

Isotechnika Inc, Edmonton, has received $21.9 million from Roche following the completion of its Phase II clinical trial of a new psoriasis drug. The $8.355 million in cash and $13.545 million in equity represents one of the largest milestone payments for a Canadian biotech company. The payment was triggered following positive results from Isotechnika’s trial of ISA247 in patients with moderate to severe psoriasis. A separate Phase II trial using the same immunosuppressant drug is being tested on kidney transplant patients. Study results are expected in late June. Isotechnika entered into a collaborative agreement with Roche in April 2002 for the global co-development and commercialization of ISA247. Under the deal, Isotechnika could receive up to US$215 million in various fees, payments and investment....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.